Clinical trials: Major Depression Disorder
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
HIV/AIDS, Clinical Depression
Zaleplon in HIV Patients With Depression
In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index…
- Trial name
- NCT03489304
- Testing
- Zaleplon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Depression
Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
To evaluate the effectiveness of one algorithm for Major Depression Disorder (MDD) using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these patients.
- Trial name
- NCT02901249
- Testing
- sertraline, Nortriptyline, Lithium
- Volunteers
- 68 people
- Sponsor
- Federal University of Rio Grande do Sul
Major Depressive Disorder
Ketamine in the Treatment of Depression
Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug.
- Trial name
- NCT01558063
- Testing
- Ketamine, Saline, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Columbia University
Major Depressive Disorder
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
- Trial name
- NCT02046564
- Testing
- ASC-01
- Where
- 29 sites in Australia, Japan and 3 more
- Volunteers
- 412 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
- Trial name
- VLZ-MD-22 (NCT02372799)
- Testing
- Vilazodone, Fluoxetine
- Where
- 60 sites in United States, Canada
- Volunteers
- 473 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Postpartum Depression
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum…
- Trial name
- NCT02942004
- Testing
- SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 138 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
- Trial name
- NCT03737474
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depression
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients.
- Trial name
- NCT00532480
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Major Depressive Disorder
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
- Trial name
- NCT00742573
- Testing
- Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B)
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy…
- Trial name
- NCT02951988
- Testing
- Rapastinel
- Where
- 137 sites in United States
- Volunteers
- 1,304 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Electroconvulsive Therapy Amplitude Titration
This study is focused on advancing ECT treatment for older adults with depressive disorders by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.
- Trial name
- NCT04621786
- Testing
- Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of New Mexico
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
The overall objective of this trial is to demonstrate clinically relevant superior antidepressant efficacy of the fixed dose combination PNB01 (low dose pipamperone and citalopram) over reference antidepressant treatment with…
- Trial name
- NCT01312922
- Testing
- PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
- Where
- 31 sites in United States, Canada
- Volunteers
- 555 people
- Sponsor
- PharmaNeuroBoost N.V.
Cancer, Severe Major Depression
Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.
- Conditions
- Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder
- Trial name
- NCT03360695
- Testing
- Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin…
- Trial name
- REVIVE (NCT01488071)
- Testing
- Vortioxetine (Lu AA21004), Agomelatine
- Volunteers
- 495 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
- Trial name
- ETS6103-003 (NCT02014363)
- Testing
- ETS6103 (low dose), ETS6103 (high dose), Amitriptyline
- Where
- United Kingdom
- Volunteers
- 164 people
- Sponsor
- e-Therapeutics PLC
Major Depressive Disorder
A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic
Despite large-scale, nationwide efforts to better address suicidal behavior in Veterans at high risk, the development of interventions that target some of the key risk factors associated with suicide remains limited.
- Trial name
- CogRemVet (NCT04952532)
- Testing
- Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development